Chemerin and its G protein-coupled receptor (ChemR23) have been associated with endothelial dysfunction, inflammation and insulin resistance. However, the role of chemerin on insulin signalling in the vasculature is still unknown. We aimed to determine whether chemerin reduces vascular insulin signalling and whether there is interplay between chemerin/ChemR23, insulin resistance and vascular complications associated with type 2 diabetes (T2D). Molecular and vascular mechanisms were probed in mesenteric arteries and cultured vascular smooth muscle cells (VSMC) from C57BL/6J, non-diabetic lean db/m and diabetic obese db/db mice as well as in human microvascular endothelial cells (HMEC). Chemerin decreased insulin-induced vasodilatation in C57BL/6J mice, an effect prevented by CCX832 (ChemR23 antagonist) treatment. In VSMC, chemerin, via oxidative stress- and ChemR23-dependent mechanisms, decreased insulin-induced Akt phosphorylation, GLUT4 translocation to the membrane and glucose uptake. In HMEC, chemerin decreased insulin-activated nitric oxide signalling. AMPK phosphorylation was reduced by chemerin in both HMEC and VSMC. CCX832 treatment of db/db mice decreased body weight, insulin and glucose levels and vascular oxidative stress. CCX832 also partially restored vascular insulin responses in db/db and high fat diet (HFD)-fed mice. Our novel in vivo findings highlight chemerin/ChemR23 as a promising therapeutic target to limit insulin resistance and vascular complications associated with obesity-related diabetes.